
About Beikang Medical
Beikang Medical is a publicly listed company based in Suzhou (China) founded in 2010. NGS-based diagnostic solutions for neonatal screening are developed. Beikang Medical has raised $36.52 million across 2 funding rounds from investors including Broad Vision Funds. The company has 497 employees. Beikang Medical has completed 1 acquisition, including BMX Holdco. Its focus areas include Life Sciences, Women Health, In Vitro Diagnostic Tests and Diversified. Its competitors include Novogene Corporation and BGI; 1 of its 2 listed competitors has raised funding.
Company details
Beikang Medical was founded in 2010 in Suzhou, China, within the genetic diagnostics sector. NGS-based solutions for neonatal and prenatal applications are developed and offered. Tests including pre-pregnancy, pre-implantation, non-invasive prenatal, and earlyneonatal genetic screening are provided under the Basecare brand. Operations are supported by Daan Gene Corp. of Sun Yat-Sen University, with the domain basecare.cn utilized.
- Headquarters Suzhou, China
- Employees 497
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website basecare.cn
- Social X Facebook
- Legal Name Suzhou Basecare Medical Corp. Ltd. Class H
- Annual Revenue$32.5 M (USD)-21.99as on Dec 31, 2025
- Net Profit-$31.13 M (USD)5.7as on Dec 31, 2025
- EBITDA-$23.2 M (USD)30.9as on Dec 31, 2025
- Total Equity Funding$36.52M (USD)
in 2 rounds
- Latest Funding Round$21.13M (USD), Series C
May 2020
- Investors
- Employee Count497
- Investments & Acquisitions
Funding Insights of Beikang Medical
Beikang Medical has successfully raised a total of $36.52M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $36.52M
- Total Rounds 2
- Last Round Series C β $21.13M
- First Round $15.38M
(Sep 2017)
- Investors Count 1
All 2 funding rounds of Beikang Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $21.13M | Series C | β | Broad Vision Funds | β |
| Sep 2017 | $15.38M | Series B | β | β | β |
1 investors in total: 1 institutional.
Investors in Beikang Medical
Beikang Medical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Broad Vision Funds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Consumer technology, healthcare, and sectors are targeted for venture investments. | broadvisionfunds.com | Beijing, China |
Investor details for Beikang Medical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Beikang Medical
Beikang Medical is a publicly listed company on the HKEX with ticker symbol 2170 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Feb 2021
- Listed onHKG: 2170
- Listed entitySuzhou Basecare Medical Corp. Ltd. Class H
- Exchange sectorHealth technology
- ISINCNE100004BC1
- Share price1.30 HKD · 2026-10-14
- Market capitalisation355,583,789.00 HKD
- EPS (diluted, trailing year)-0.71 HKD
- Volume (last session)13,500
Financials of Beikang Medical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 253.0M HKD | -242.3M HKD | -180.6M HKD |
| 2024 | 324.3M HKD | -257.0M HKD | -261.4M HKD |
| 2023 | 229.8M HKD | -211.8M HKD | -251.9M HKD |
| 2022 | 163.8M HKD | -153.2M HKD | -249.1M HKD |
| 2021 | 129.3M HKD | -173.1M HKD | -146.2M HKD |
Detailed financial statements for Beikang Medical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beikang Medical
Beikang Medical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BMX Holdco.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Multiple industries are operated by the diversified conglomerate. | Singapore | 2022 | May 2023 | β’β’β’β’ |
Complete acquisition details for Beikang Medical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Beikang Medical
5 dated milestones of Beikang Medical across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Beikang Medical is founded.
- Funding First funding round of $15.4M.
- Funding Latest funding round, Series C, of $21.1M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires BMX Holdco.
Competitors of Beikang Medical
Beikang Medical has 2 listed competitors in our database, 1 of them funded. They include Novogene Corporation and BGI.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| bgi.com | 1999 | Shenzhen, China | 25 | BGI is engaged in genomics and precision medicine solutions. |
Detailed competitors of Beikang Medical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Beikang Medical
The website of Beikang Medical (basecare.cn) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 83.5% vs previous month
Websites whose visitors overlap most with Beikang Medical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| orbusneich.com | 100% | 9K | #2,415,384 | View details | |
tiantu.com.cn | tiantu.com.cn | 78% | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beikang Medical
Complete news archive for Beikang Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beikang Medical
Beikang Medical was founded in 2010 and raised its 1st funding round 7 years after it was founded.
Beikang Medical is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Beikang Medical is a funded company, having raised a total of $36.52M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15.38M, raised on Sep 2017.
Beikang Medical has 497 employees.
Annual revenue of Beikang Medical is $32.5M as on Dec 31, 2025.
Beikang Medical was founded in 2010 in Suzhou, China, within the genetic diagnostics sector. NGS-based solutions for neonatal and prenatal applications are developed and offered. Tests including pre-pregnancy, pre-implantation, non-invasive prenatal, and earlyneonatal genetic screening are provided under the Basecare brand. Operations are supported by Daan Gene Corp. of Sun Yat-Sen University, with the domain basecare.cn utilized.
Beikang Medical's top competitors include Novogene Corporation and BGI.
Yes, Beikang Medical is publicly traded on HKEX under the ticker symbol 2170.
Beikang Medical has made 1 acquisition, including BMX Holdco.
Beikang Medical has 1 investor. Key investors include Broad Vision Funds.
